GSK halts Phase II trials evaluating feladilimab in the treatment of head and neck squamous cell carcinoma (HNSCC)

Feladilimab is an inducible T cell co-stimulatory agonist, which has previously shown promising anti-tumour activity in combination with pembrolizumab in HNSCC. The INDUCE-3 trial was halted following a recommendation from the Independent Data Monitoring Committee.

Source:

PharmaTimes